These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 18231106)

  • 1. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
    Bucher N; Britten CD
    Br J Cancer; 2008 Feb; 98(3):523-8. PubMed ID: 18231106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
    Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chk1 inhibitors for novel cancer treatment.
    Tao ZF; Lin NH
    Anticancer Agents Med Chem; 2006 Jul; 6(4):377-88. PubMed ID: 16842237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into checkpoint kinase 1 in the DNA damage response signaling network.
    Dai Y; Grant S
    Clin Cancer Res; 2010 Jan; 16(2):376-83. PubMed ID: 20068082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage.
    Jackson JR; Gilmartin A; Imburgia C; Winkler JD; Marshall LA; Roshak A
    Cancer Res; 2000 Feb; 60(3):566-72. PubMed ID: 10676638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
    Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
    Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the S and G2 checkpoint to treat cancer.
    Chen T; Stephens PA; Middleton FK; Curtin NJ
    Drug Discov Today; 2012 Mar; 17(5-6):194-202. PubMed ID: 22192883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells.
    Koniaras K; Cuddihy AR; Christopoulos H; Hogg A; O'Connell MJ
    Oncogene; 2001 Nov; 20(51):7453-63. PubMed ID: 11709716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cell cycle regulation after exposure to ionizing radiation].
    Teyssier F; Bay JO; Dionet C; Verrelle P
    Bull Cancer; 1999 Apr; 86(4):345-57. PubMed ID: 10341340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA damage checkpoint kinases in cancer.
    Smith HL; Southgate H; Tweddle DA; Curtin NJ
    Expert Rev Mol Med; 2020 Jun; 22():e2. PubMed ID: 32508294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
    Xiao Z; Xue J; Sowin TJ; Zhang H
    Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.
    McNeely S; Beckmann R; Bence Lin AK
    Pharmacol Ther; 2014 Apr; 142(1):1-10. PubMed ID: 24140082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
    Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics.
    Ma CX; Janetka JW; Piwnica-Worms H
    Trends Mol Med; 2011 Feb; 17(2):88-96. PubMed ID: 21087899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.
    Barnaba N; LaRocque JR
    Cell Cycle; 2021 Jun; 20(11):1041-1051. PubMed ID: 33966611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unleashing Chk1 in cancer therapy.
    Carrassa L; Damia G
    Cell Cycle; 2011 Jul; 10(13):2121-8. PubMed ID: 21610326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.
    Xiao Z; Chen Z; Gunasekera AH; Sowin TJ; Rosenberg SH; Fesik S; Zhang H
    J Biol Chem; 2003 Jun; 278(24):21767-73. PubMed ID: 12676925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer.
    Li Q; Zhu GD
    Curr Top Med Chem; 2002 Sep; 2(9):939-71. PubMed ID: 12171565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
    Leijen S; Beijnen JH; Schellens JH
    Curr Clin Pharmacol; 2010 Aug; 5(3):186-91. PubMed ID: 20406171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.